ID   PLCG2_RAT               Reviewed;        1265 AA.
AC   P24135;
DT   01-MAR-1992, integrated into UniProtKB/Swiss-Prot.
DT   01-MAR-1992, sequence version 1.
DT   29-MAY-2024, entry version 195.
DE   RecName: Full=1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase gamma-2 {ECO:0000305};
DE            EC=3.1.4.11 {ECO:0000250|UniProtKB:P16885};
DE   AltName: Full=Phosphoinositide phospholipase C-gamma-2;
DE   AltName: Full=Phospholipase C-IV;
DE            Short=PLC-IV;
DE   AltName: Full=Phospholipase C-gamma-2;
DE            Short=PLC-gamma-2;
GN   Name=Plcg2 {ECO:0000312|RGD:3348};
OS   Rattus norvegicus (Rat).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Glires; Rodentia; Myomorpha; Muroidea; Muridae;
OC   Murinae; Rattus.
OX   NCBI_TaxID=10116;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Muscle;
RX   PubMed=2557343; DOI=10.1016/s0021-9258(20)88267-2;
RA   Emori Y., Homma Y., Sorimachi H., Kawasaki H., Nakanishi O., Suzuki K.,
RA   Takenawa T.;
RT   "A second type of rat phosphoinositide-specific phospholipase C containing
RT   a src-related sequence not essential for phosphoinositide-hydrolyzing
RT   activity.";
RL   J. Biol. Chem. 264:21885-21890(1989).
RN   [2]
RP   PHOSPHORYLATION AT TYR-1197.
RX   PubMed=10498607;
RA   Hashimoto S., Iwamatsu A., Ishiai M., Okawa K., Yamadori T., Matsushita M.,
RA   Baba Y., Kishimoto T., Kurosaki T., Tsukada S.;
RT   "Identification of the SH2 domain binding protein of Bruton's tyrosine
RT   kinase as BLNK--functional significance of Btk-SH2 domain in B-cell antigen
RT   receptor-coupled calcium signaling.";
RL   Blood 94:2357-2364(1999).
RN   [3]
RP   STRUCTURE BY NMR OF 633-744.
RG   RIKEN structural genomics initiative (RSGI);
RT   "Solution structure of the second SH2 domain from rat PLC gamma-2.";
RL   Submitted (APR-2008) to the PDB data bank.
CC   -!- FUNCTION: The production of the second messenger molecules
CC       diacylglycerol (DAG) and inositol 1,4,5-trisphosphate (IP3) is mediated
CC       by activated phosphatidylinositol-specific phospholipase C enzymes. It
CC       is a crucial enzyme in transmembrane signaling.
CC       {ECO:0000250|UniProtKB:P16885}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=a 1,2-diacyl-sn-glycero-3-phospho-(1D-myo-inositol-4,5-
CC         bisphosphate) + H2O = 1D-myo-inositol 1,4,5-trisphosphate + a 1,2-
CC         diacyl-sn-glycerol + H(+); Xref=Rhea:RHEA:33179, ChEBI:CHEBI:15377,
CC         ChEBI:CHEBI:15378, ChEBI:CHEBI:17815, ChEBI:CHEBI:58456,
CC         ChEBI:CHEBI:203600; EC=3.1.4.11;
CC         Evidence={ECO:0000250|UniProtKB:P16885};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:33180;
CC         Evidence={ECO:0000250|UniProtKB:P16885};
CC   -!- COFACTOR:
CC       Name=Ca(2+); Xref=ChEBI:CHEBI:29108;
CC   -!- SUBUNIT: Part of a complex composed of EEIG1, TNFRSF11A/RANK, PLCG2,
CC       GAB2, TEC and BTK; complex formation increases in the presence of
CC       TNFSF11/RANKL (By similarity). Interacts (via SH2 domain) with CSF1R
CC       (tyrosine phosphorylated). Interacts constitutively with THEMIS2.
CC       {ECO:0000250|UniProtKB:Q8CIH5}.
CC   -!- SUBCELLULAR LOCATION: Membrane raft {ECO:0000250|UniProtKB:Q8CIH5}.
CC   -!- PTM: Phosphorylated on tyrosine residues by CSF1R (By similarity).
CC       Phosphorylated on tyrosine residues by BTK and SYK; upon ligand-induced
CC       activation of a variety of growth factor receptors and immune system
CC       receptors. Phosphorylation leads to increased phospholipase activity
CC       (By similarity). {ECO:0000250|UniProtKB:P16885,
CC       ECO:0000250|UniProtKB:Q8CIH5}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; J05155; AAA41896.1; -; mRNA.
DR   PIR; A34163; A34163.
DR   RefSeq; NP_058864.1; NM_017168.1.
DR   PDB; 2EOB; NMR; -; A=633-743.
DR   PDBsum; 2EOB; -.
DR   AlphaFoldDB; P24135; -.
DR   BMRB; P24135; -.
DR   SMR; P24135; -.
DR   IntAct; P24135; 5.
DR   STRING; 10116.ENSRNOP00000069801; -.
DR   ChEMBL; CHEMBL5230; -.
DR   iPTMnet; P24135; -.
DR   PhosphoSitePlus; P24135; -.
DR   PaxDb; 10116-ENSRNOP00000018678; -.
DR   GeneID; 29337; -.
DR   KEGG; rno:29337; -.
DR   UCSC; RGD:3348; rat.
DR   AGR; RGD:3348; -.
DR   CTD; 5336; -.
DR   RGD; 3348; Plcg2.
DR   eggNOG; KOG1264; Eukaryota.
DR   InParanoid; P24135; -.
DR   OrthoDB; 2900494at2759; -.
DR   PhylomeDB; P24135; -.
DR   Reactome; R-RNO-114604; GPVI-mediated activation cascade.
DR   Reactome; R-RNO-166016; Toll Like Receptor 4 (TLR4) Cascade.
DR   Reactome; R-RNO-1855204; Synthesis of IP3 and IP4 in the cytosol.
DR   Reactome; R-RNO-202433; Generation of second messenger molecules.
DR   Reactome; R-RNO-2029485; Role of phospholipids in phagocytosis.
DR   Reactome; R-RNO-2424491; DAP12 signaling.
DR   Reactome; R-RNO-2871796; FCERI mediated MAPK activation.
DR   Reactome; R-RNO-2871809; FCERI mediated Ca+2 mobilization.
DR   Reactome; R-RNO-5607764; CLEC7A (Dectin-1) signaling.
DR   Reactome; R-RNO-5621480; Dectin-2 family.
DR   Reactome; R-RNO-983695; Antigen activates B Cell Receptor (BCR) leading to generation of second messengers.
DR   EvolutionaryTrace; P24135; -.
DR   PRO; PR:P24135; -.
DR   Proteomes; UP000002494; Unplaced.
DR   GO; GO:0005737; C:cytoplasm; ISO:RGD.
DR   GO; GO:0005829; C:cytosol; ISO:RGD.
DR   GO; GO:0097708; C:intracellular vesicle; ISO:RGD.
DR   GO; GO:0045121; C:membrane raft; ISS:UniProtKB.
DR   GO; GO:0048471; C:perinuclear region of cytoplasm; ISO:RGD.
DR   GO; GO:0005886; C:plasma membrane; ISS:UniProtKB.
DR   GO; GO:0032587; C:ruffle membrane; ISO:RGD.
DR   GO; GO:0004435; F:phosphatidylinositol phospholipase C activity; IDA:RGD.
DR   GO; GO:0140031; F:phosphorylation-dependent protein binding; ISO:RGD.
DR   GO; GO:0001784; F:phosphotyrosine residue binding; ISO:RGD.
DR   GO; GO:0019901; F:protein kinase binding; ISO:RGD.
DR   GO; GO:1990782; F:protein tyrosine kinase binding; ISO:RGD.
DR   GO; GO:0097110; F:scaffold protein binding; ISO:RGD.
DR   GO; GO:0061760; P:antifungal innate immune response; ISO:RGD.
DR   GO; GO:0030183; P:B cell differentiation; ISO:RGD.
DR   GO; GO:0050853; P:B cell receptor signaling pathway; ISO:RGD.
DR   GO; GO:0019722; P:calcium-mediated signaling; ISO:RGD.
DR   GO; GO:0001775; P:cell activation; ISO:RGD.
DR   GO; GO:0071277; P:cellular response to calcium ion; ISO:RGD.
DR   GO; GO:1990858; P:cellular response to lectin; ISO:RGD.
DR   GO; GO:0071396; P:cellular response to lipid; ISO:RGD.
DR   GO; GO:0002316; P:follicular B cell differentiation; ISO:RGD.
DR   GO; GO:0032959; P:inositol trisphosphate biosynthetic process; ISO:RGD.
DR   GO; GO:0035556; P:intracellular signal transduction; IMP:ARUK-UCL.
DR   GO; GO:0031663; P:lipopolysaccharide-mediated signaling pathway; ISO:RGD.
DR   GO; GO:0002281; P:macrophage activation involved in immune response; ISO:RGD.
DR   GO; GO:0043069; P:negative regulation of programmed cell death; ISO:RGD.
DR   GO; GO:0006661; P:phosphatidylinositol biosynthetic process; ISS:UniProtKB.
DR   GO; GO:0046488; P:phosphatidylinositol metabolic process; IBA:GO_Central.
DR   GO; GO:0048015; P:phosphatidylinositol-mediated signaling; IBA:GO_Central.
DR   GO; GO:0009395; P:phospholipid catabolic process; IEA:InterPro.
DR   GO; GO:0050850; P:positive regulation of calcium-mediated signaling; ISO:RGD.
DR   GO; GO:1902808; P:positive regulation of cell cycle G1/S phase transition; IDA:ARUK-UCL.
DR   GO; GO:0007204; P:positive regulation of cytosolic calcium ion concentration; IMP:RGD.
DR   GO; GO:0002732; P:positive regulation of dendritic cell cytokine production; ISO:RGD.
DR   GO; GO:0051091; P:positive regulation of DNA-binding transcription factor activity; IMP:ARUK-UCL.
DR   GO; GO:0010634; P:positive regulation of epithelial cell migration; IBA:GO_Central.
DR   GO; GO:0010628; P:positive regulation of gene expression; IMP:ARUK-UCL.
DR   GO; GO:1903721; P:positive regulation of I-kappaB phosphorylation; ISO:RGD.
DR   GO; GO:0032733; P:positive regulation of interleukin-10 production; ISO:RGD.
DR   GO; GO:0032735; P:positive regulation of interleukin-12 production; ISO:RGD.
DR   GO; GO:0032743; P:positive regulation of interleukin-2 production; ISO:RGD.
DR   GO; GO:0032747; P:positive regulation of interleukin-23 production; ISO:RGD.
DR   GO; GO:0032755; P:positive regulation of interleukin-6 production; ISO:RGD.
DR   GO; GO:0060907; P:positive regulation of macrophage cytokine production; ISO:RGD.
DR   GO; GO:0043410; P:positive regulation of MAPK cascade; ISO:RGD.
DR   GO; GO:0150078; P:positive regulation of neuroinflammatory response; ISO:RGD.
DR   GO; GO:1900227; P:positive regulation of NLRP3 inflammasome complex assembly; ISO:RGD.
DR   GO; GO:0050731; P:positive regulation of peptidyl-tyrosine phosphorylation; ISO:RGD.
DR   GO; GO:0060100; P:positive regulation of phagocytosis, engulfment; ISO:RGD.
DR   GO; GO:1903428; P:positive regulation of reactive oxygen species biosynthetic process; ISO:RGD.
DR   GO; GO:0002092; P:positive regulation of receptor internalization; ISO:RGD.
DR   GO; GO:0032760; P:positive regulation of tumor necrosis factor production; ISO:RGD.
DR   GO; GO:0032481; P:positive regulation of type I interferon production; ISO:RGD.
DR   GO; GO:0012501; P:programmed cell death; ISO:RGD.
DR   GO; GO:0070884; P:regulation of calcineurin-NFAT signaling cascade; ISO:RGD.
DR   GO; GO:0043122; P:regulation of canonical NF-kappaB signal transduction; ISO:RGD.
DR   GO; GO:0010468; P:regulation of gene expression; ISO:RGD.
DR   GO; GO:0019216; P:regulation of lipid metabolic process; ISO:RGD.
DR   GO; GO:0051209; P:release of sequestered calcium ion into cytosol; ISS:UniProtKB.
DR   GO; GO:0033198; P:response to ATP; IDA:RGD.
DR   GO; GO:0048678; P:response to axon injury; ISO:RGD.
DR   GO; GO:0032496; P:response to lipopolysaccharide; ISO:RGD.
DR   GO; GO:0032026; P:response to magnesium ion; IDA:RGD.
DR   GO; GO:0001878; P:response to yeast; ISO:RGD.
DR   GO; GO:0002223; P:stimulatory C-type lectin receptor signaling pathway; ISO:RGD.
DR   GO; GO:0050852; P:T cell receptor signaling pathway; ISO:RGD.
DR   GO; GO:0002224; P:toll-like receptor signaling pathway; ISO:RGD.
DR   CDD; cd00275; C2_PLC_like; 1.
DR   CDD; cd16215; EFh_PI-PLCgamma2; 1.
DR   CDD; cd13362; PH_PLC_gamma; 1.
DR   CDD; cd13234; PHsplit_PLC_gamma; 1.
DR   CDD; cd08592; PI-PLCc_gamma; 1.
DR   CDD; cd09932; SH2_C-SH2_PLC_gamma_like; 1.
DR   CDD; cd10341; SH2_N-SH2_PLC_gamma_like; 1.
DR   CDD; cd11969; SH3_PLCgamma2; 1.
DR   Gene3D; 2.60.40.150; C2 domain; 1.
DR   Gene3D; 3.20.20.190; Phosphatidylinositol (PI) phosphodiesterase; 2.
DR   Gene3D; 2.30.29.30; Pleckstrin-homology domain (PH domain)/Phosphotyrosine-binding domain (PTB); 1.
DR   Gene3D; 3.30.505.10; SH2 domain; 2.
DR   Gene3D; 2.30.30.40; SH3 Domains; 1.
DR   InterPro; IPR000008; C2_dom.
DR   InterPro; IPR035892; C2_domain_sf.
DR   InterPro; IPR011992; EF-hand-dom_pair.
DR   InterPro; IPR011993; PH-like_dom_sf.
DR   InterPro; IPR001849; PH_domain.
DR   InterPro; IPR001192; PI-PLC_fam.
DR   InterPro; IPR016279; PLC-gamma.
DR   InterPro; IPR035023; PLC-gamma_C-SH2.
DR   InterPro; IPR035024; PLC-gamma_N-SH2.
DR   InterPro; IPR017946; PLC-like_Pdiesterase_TIM-brl.
DR   InterPro; IPR035723; PLCgamma2_SH3.
DR   InterPro; IPR000909; PLipase_C_PInositol-sp_X_dom.
DR   InterPro; IPR001711; PLipase_C_Pinositol-sp_Y.
DR   InterPro; IPR000980; SH2.
DR   InterPro; IPR036860; SH2_dom_sf.
DR   InterPro; IPR036028; SH3-like_dom_sf.
DR   InterPro; IPR001452; SH3_domain.
DR   PANTHER; PTHR10336:SF25; 1-PHOSPHATIDYLINOSITOL 4,5-BISPHOSPHATE PHOSPHODIESTERASE GAMMA-2; 1.
DR   PANTHER; PTHR10336; PHOSPHOINOSITIDE-SPECIFIC PHOSPHOLIPASE C FAMILY PROTEIN; 1.
DR   Pfam; PF00168; C2; 1.
DR   Pfam; PF00388; PI-PLC-X; 1.
DR   Pfam; PF00387; PI-PLC-Y; 1.
DR   Pfam; PF00017; SH2; 2.
DR   Pfam; PF00018; SH3_1; 1.
DR   PIRSF; PIRSF000952; PLC-gamma; 1.
DR   PRINTS; PR00390; PHPHLIPASEC.
DR   PRINTS; PR00401; SH2DOMAIN.
DR   SMART; SM00239; C2; 1.
DR   SMART; SM00233; PH; 2.
DR   SMART; SM00148; PLCXc; 1.
DR   SMART; SM00149; PLCYc; 1.
DR   SMART; SM00252; SH2; 2.
DR   SMART; SM00326; SH3; 1.
DR   SUPFAM; SSF49562; C2 domain (Calcium/lipid-binding domain, CaLB); 1.
DR   SUPFAM; SSF47473; EF-hand; 1.
DR   SUPFAM; SSF50729; PH domain-like; 1.
DR   SUPFAM; SSF51695; PLC-like phosphodiesterases; 1.
DR   SUPFAM; SSF55550; SH2 domain; 2.
DR   SUPFAM; SSF50044; SH3-domain; 1.
DR   PROSITE; PS50004; C2; 1.
DR   PROSITE; PS50003; PH_DOMAIN; 1.
DR   PROSITE; PS50007; PIPLC_X_DOMAIN; 1.
DR   PROSITE; PS50008; PIPLC_Y_DOMAIN; 1.
DR   PROSITE; PS50001; SH2; 2.
DR   PROSITE; PS50002; SH3; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Calcium; Hydrolase; Lipid degradation; Lipid metabolism;
KW   Membrane; Phosphoprotein; Reference proteome; Repeat; SH2 domain;
KW   SH3 domain; Transducer.
FT   CHAIN           1..1265
FT                   /note="1-phosphatidylinositol 4,5-bisphosphate
FT                   phosphodiesterase gamma-2"
FT                   /id="PRO_0000088502"
FT   DOMAIN          20..131
FT                   /note="PH"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00145"
FT   DOMAIN          312..456
FT                   /note="PI-PLC X-box"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00270"
FT   DOMAIN          532..635
FT                   /note="SH2 1"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00191"
FT   DOMAIN          646..735
FT                   /note="SH2 2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00191"
FT   DOMAIN          769..829
FT                   /note="SH3"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00192"
FT   DOMAIN          930..1044
FT                   /note="PI-PLC Y-box"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00271"
FT   DOMAIN          1038..1169
FT                   /note="C2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00041"
FT   ACT_SITE        327
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00270"
FT   ACT_SITE        372
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00270"
FT   MOD_RES         753
FT                   /note="Phosphotyrosine; by BTK"
FT                   /evidence="ECO:0000250|UniProtKB:P16885"
FT   MOD_RES         759
FT                   /note="Phosphotyrosine; by BTK"
FT                   /evidence="ECO:0000250|UniProtKB:P16885"
FT   MOD_RES         1197
FT                   /note="Phosphotyrosine; by BTK"
FT                   /evidence="ECO:0000269|PubMed:10498607"
FT   MOD_RES         1217
FT                   /note="Phosphotyrosine"
FT                   /evidence="ECO:0000250|UniProtKB:P16885"
FT   MOD_RES         1245
FT                   /note="Phosphotyrosine"
FT                   /evidence="ECO:0000250|UniProtKB:P16885"
FT   TURN            641..643
FT                   /evidence="ECO:0007829|PDB:2EOB"
FT   STRAND          647..650
FT                   /evidence="ECO:0007829|PDB:2EOB"
FT   HELIX           653..662
FT                   /evidence="ECO:0007829|PDB:2EOB"
FT   STRAND          665..672
FT                   /evidence="ECO:0007829|PDB:2EOB"
FT   STRAND          680..686
FT                   /evidence="ECO:0007829|PDB:2EOB"
FT   STRAND          689..700
FT                   /evidence="ECO:0007829|PDB:2EOB"
FT   STRAND          702..707
FT                   /evidence="ECO:0007829|PDB:2EOB"
FT   STRAND          710..712
FT                   /evidence="ECO:0007829|PDB:2EOB"
FT   HELIX           713..720
FT                   /evidence="ECO:0007829|PDB:2EOB"
FT   STRAND          725..728
FT                   /evidence="ECO:0007829|PDB:2EOB"
FT   HELIX           737..742
FT                   /evidence="ECO:0007829|PDB:2EOB"
SQ   SEQUENCE   1265 AA;  147735 MW;  2C34910D43572723 CRC64;
     MTTMVNVDTL PEYEKSQIKR ALELGTVMTV FSARKSTPER RTVQMIMETR QVAWSKTADK
     IEGFLDIMEI KEIRPGKNSK DFERAKAVRH KADCCFTIFY GTQFVLSTLS LATDSKEDAV
     KWLSGLKILH QEAMNASTPT MIESWLRKQI YSVDQTRRNS ISLRELKTIL PLVNFKVSGI
     KFLKDKLVEI GAQKDELSFE QFHLFYKKLM FEQQKSILDE FKKDSSVFIL GNTDRPDASA
     VYLQDFQRFL LHEQQELWAQ DLNKVRERMT KFIDDTMRET AEPFLFVDEF LTYLFSRENS
     IWDEKYDAVD MQDMNNPLSH YWISSSHNTY LTGDQLRSES STEAYIRCLR AGCRCIELDC
     WDGPDGKPII YHGWTRTTKI KFDDVVQAIR DHAFVTSSFP VILSIEEHCS VEQQRHMAKV
     FKEVLGDLLL TKPTEASADQ LPSPSQLREK IIIKHKKLGP RGDVDVNVED KKDEHKTQGE
     LYMWDSIDQK WTRHYCAIAD AKLSFSDDIE QTVEEDPVQD TPPTELHFGE KWFHKKVESR
     TSAEKLLQEY CAETGAKDGT FLVRESETFP NDYTLSFWRS GRVQHCRIRS TMEGGVMKYY
     LTDNLTFNSI YALIQHYREA HLRCAEFELR LTDPVPNPNP HESKPWYYDR LSRGEAEDML
     MRIPRDGAFL IRKREGTDSY AITFRARGKV KHCRINRDGR HFVLGTSAYF ESLVELVSYY
     EKHALYRKMR LRYPVTPELL ERYNMERDIN SLYDVSRMYV DPSEINPSMP QRTVKALYDY
     KAKRSDELTF CRGALIHNVS KEPGGWWKGD YGTRIQQYFP SNYVEDISAG DAEEMEKQII
     EDNPLGSLCR GILDLNTYNV VKAPQGKNQK AFVFILEPKK QGDPPVEFAT DRVEELFEWF
     QSIREITWKI DTKENNMKYW ERNQSIAIEL SDLVVYCKPT SKTKDHLENP DFREIRSFVE
     TKADSIVRQK PVDLLRYNQK GLTRVYPKGQ RVDSSNYDPF RLWLCGSQMV ALNFQTPDKY
     MQMNHALFSL NGRTGYVLQP ESMRSEKYDP MPPESQRKIL MTLTVKVLGA RHLPKLGRSI
     ACPFVEVEIC GAEYDSNKFK TTVVNDNGLS PVWAPTQEKV TFEIYDPNLA FLRFLVYEED
     MFSDPNFLAH ATYPIKGIKS GFRSVPLKNG YSEDIELASL LVFCEMRPVL ESEEELYSSC
     RQLRRRQEEL NNQLFLYDTH QNLRGANRDA LVKEFNVNEN QLRLYQEKCN RRLREKRVSN
     SRFYS
//
